Coherus Biosciences (CHRS) PT Raised to $25 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Coherus Biosciences (CHRS) PT Raised to $25 at Citi Following 4Q and FDA Meeting
March 9, 2018 7:20 AM ESTCiti raised its price target on Coherus Biosciences (NASDAQ: CHRS) to $25.00 (from $23.00) while maintaining a Buy rating following the company's 4Q earnings report. Management highlighted the company's FDA meeting and the discussion of immunogenicity assay for Neulasta biosimilar. They noted that the... More
Coherus Biosciences (CHRS) PT Lowered to $15 at Maxim Group
March 9, 2018 6:59 AM ESTMaxim Group lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $15.00 (from $20.00) while maintaining a Buy rating.
... More